Cyclopharm logo
CYCCyclopharm
Trade CYC now
Cyclopharm primary media

About Cyclopharm

Cyclopharm (ASX:CYC) is a nuclear medicine company that develops, manufactures, and markets radiopharmaceuticals for the diagnosis and treatment of disease. The company’s flagship product is Technegas, which is a radiopharmaceutical used for functional lung ventilation imaging.

What is CYC known for?

Snapshot

Public AU
Ownership
1986
Year founded
10
Employees
New South Wales, Australia
Head office
1 of 545
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Australia

Produtos e/ou serviços de Cyclopharm

  • Technegas: A radiopharmaceutical used for functional lung ventilation imaging.
  • Research and development: Cyclopharm is actively engaged in research and development, with a focus on developing new radiopharmaceuticals for the diagnosis and treatment of pulmonary diseases.

equipe executiva do Cyclopharm

  • Mr. James S. McBrayer AIM, BSPharm, F.A.C.I.D., FAICD, GDMCEO, MD, Company Secretary & Director
  • Mr. Jason SmithChief Financial Officer
  • Mr. Mathew FaragChief Operating Officer
  • Ms. Sally-Ann CorneliusHead of Sales
  • Ms. Niamh McAreeHead of Quality and Regulatory
  • Mr. Chris QuinnHead of Service
  • Ms. Sui Ling CheahFinancial Controller
  • Mr. Lynn McLauchlinGeneral Manager of Canada
  • Mr. Gary T. SomervilleQuality & Regulatory Manager

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.